Some Black women with hormone receptor (HR)-positive/HER2-negative breast cancer had worse outcomes compared with White women despite having similar genetic recurrence risk scores, according to data from the 2022 San Antonio Breast Cancer Symposium. Yara Abdou, MD, assistant professor at the University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, presented results of an analysis of clinical outcomes respective to race and ethnicity in women enrolled in the RxPONDER trial. The trial aimed to assess the value of the 21-gene recurrence score (RS) in patients with ...
SABCS 2022
The San Antonio Breast Cancer Symposium (SABCS) is the largest and most prestigious scientific gathering on breast cancer research. Topics cover new treatments, patient care, surgical and reconstructive techniques, health equity, telemedicine, and more. Find highlights from the sessions that are most relevant to oncology nurses.
Advertisement
Results from the DESTINY-Breast03 study indicate survival advantage with the antibody drug conjugate.
The local recurrence rates were optimistic for women with multiple ipsilateral breast cancer in one clinical trial.
Advertisement
Less than half of patients with cancer had caregivers who spoke for more than 4% of a clinical encounter.
Learn how a personalized 12-week exercise program can enhance quality of life outcomes in survivors of breast cancer.
Researchers analyzed if the intervention could improve negative emotions, quality of life, and satisfaction with nursing.
A new study highlights the effectiveness of a nurse navigation program for patients undergoing treatment for these cancers.
Researchers aimed to identify the best timing for telenursing follow-up after chemotherapy.
There are several important nursing considerations to keep in mind when evaluating a patient’s risk for breast cancer.